Abstract

We have recently demonstrated that sciatic nerve injury increases the expression of spinal cytochrome P450c17, a key neurosteroidogenic enzyme, which plays a critical role in the development of peripheral neuropathic pain. However, the modulatory mechanisms responsible for the expression of spinal P450c17 have yet to be examined. Here we investigated the possible involvement of interleukin-1β (IL-1β) in altering P450c17 expression during the induction phase of neuropathic pain. Neuropathic pain was produced by chronic constriction injury (CCI) of the right sciatic nerve in mice and mechanical allodynia was evaluated in the hind paws using a von-Frey filament (0.16 g). Western blotting and immunohistochemistry were performed to assess the expression of spinal IL-1β, interleukin-1 receptor type 1 (IL-1R1), P450c17, and GFAP. Spinal IL-1β was significantly increased on day 1 post-surgery and its receptor, IL-1R1 was expressed in GFAP-positive astrocytes. Intrathecal administration of the recombinant interleukin-1 receptor antagonist (IL-1ra, 20 ng) on days 0 and 1 post-surgery enhanced GFAP expression on day 1 post-surgery and induced an early increase in P450c17 expression in astrocytes, but not in neurons. Administration of IL-1β (10 ng) on days 0 and 1 post-surgery blocked the enhancement of both spinal P450c17 and GFAP expression induced by IL-1ra (20 ng) administration. Intrathecal administration of IL-1ra (20 ng) on days 0 to 3 post-surgery also facilitated the CCI-induced development of mechanical allodynia, and this early developed pain was dose-dependently attenuated by the administration of the P450c17 inhibitor, ketoconazole (1, 3, or 10 nmol) or the astrocyte metabolic inhibitor, fluorocitrate (0.01, 0.03, or 0.1 nmol). These results demonstrate that early increases in spinal IL-1β temporally inhibit astrocyte P450c17 expression and astrocyte activation ultimately controlling the development of mechanical allodynia induced by peripheral nerve injury. These findings imply that spinal IL-1β plays an important role as an early, but transient, control mechanism in the development of peripheral neuropathic pain via the inhibition of astrocyte P450c17 expression and astrocyte activation.

Highlights

  • IntroductionNeuropathic pain develops following injury to the nervous system and is often characterized by allodynia (the sensation of pain to non-noxious stimuli) and hyperalgesia (increased pain to a noxious stimuli) (Woolf and Mannion, 1999)

  • Neuropathic pain develops following injury to the nervous system and is often characterized by allodynia and hyperalgesia (Woolf and Mannion, 1999)

  • The present study was designed to determine whether IL-1β modulates astrocyte P450c17 expression and astrocyte activation in the spinal cord and to determine whether this modulation alters the development of neuropathic pain following peripheral nerve injury. To accomplish this we investigated whether: (i) sciatic nerve injury increases the expression of IL-1β in the lumbar spinal cord dorsal horn; (ii) IL-1R1, a functional receptor of IL1β, is expressed in spinal astrocytes; (iii) the blockade of IL-1R1 using the recombinant IL-1 receptor antagonist (IL-1ra) modulates astrocyte P450c17 expression and pathological astrocyte activation; and (iv) this modulation is associated with the development of mechanical stimuli (MA) induced by peripheral nerve injury

Read more

Summary

Introduction

Neuropathic pain develops following injury to the nervous system and is often characterized by allodynia (the sensation of pain to non-noxious stimuli) and hyperalgesia (increased pain to a noxious stimuli) (Woolf and Mannion, 1999). The development of neuropathic pain involves a variety of pathophysiological changes in the nervous system, which are represented by peripheral sensitization (increased sensitivity of the nociceptor terminal) and central sensitization (increased synaptic efficacy of neurons in the spinal pain pathways) (Ji et al, 2003; Latremoliere and Woolf, 2009). Once neuropathic pain has been established it is very difficult to control. Even with well-established medications, effectiveness is unpredictable, dosing can be complicated, analgesic onset is delayed, and side effects are common (Dworkin et al, 2007). As a result it is necessary to investigate and develop more effective therapeutic approaches based on the pathophysiological mechanisms underlying the development of neuropathic pain

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call